<html xmlns="http://www.w3.org/1999/xhtml" xmlns="http://www.w3.org/1999/xhtml">
 <head xmlns="http://www.w3.org/1999/xhtml">
 <title xmlns="http://www.w3.org/1999/xhtml"></title>
 </head>
 <body xmlns="http://www.w3.org/1999/xhtml">
 
 <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.iconplc.com&amp;esheet=51512072&amp;newsitemid=20170220005035&amp;lan=en-US&amp;anchor=ICON+plc&amp;index=1&amp;md5=9aeabf188fbc7fa5f0649d0d20927886" rel="nofollow" rel="nofollow">ICON 
 plc</a>, ICLR a global provider of drug development 
 solutions and services to the pharmaceutical, biotechnology and medical 
 device industries, today announced that it has been awarded a project by 
 the <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fda.gov%2F&amp;esheet=51512072&amp;newsitemid=20170220005035&amp;lan=en-US&amp;anchor=US+Food+%26+Drug+Administration&amp;index=2&amp;md5=34190e833f4c7c7e325c2149dc198280" rel="nofollow" rel="nofollow">US 
 Food &amp; Drug Administration</a> (FDA) to validate three Patient 
 Reported Outcomes (PRO) instruments that will measure clinical endpoints 
 in antibacterial drug trials. The conditions in which the endpoints will 
 be validated are Acute Bacterial Skin and Skin Structure Infections 
 (ABSSSI), Community-Acquired Bacterial Pneumonia (CABP) and 
 Hospital-Acquired Bacterial Pneumonia (HABP).
 
 
 HABP is the second most common hospital-acquired infection and is the 
 primary cause of death in intensive care units; ABSSSI has high rates of 
 morbidity and other associated medical conditions whilst CABP is a major 
 cause of mortality and morbidity worldwide, particularly among people 
 over 65 years of age. Sponsors engaged in clinical trials for these 
 conditions are currently using different methodologies to assess the 
 primary endpoint as there is no qualified PRO instrument.
 
 
 ICON's Clinical Outcomes Assessment (COA) group, in collaboration with 
 the <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.biomarkersconsortium.org%2F&amp;esheet=51512072&amp;newsitemid=20170220005035&amp;lan=en-US&amp;anchor=Biomarkers+Consortium%C2%A0&amp;index=3&amp;md5=4fc1b8007695d2231a148a410db5ce82" rel="nofollow" rel="nofollow">Biomarkers 
 Consortium </a>of the <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fnih.org%2F&amp;esheet=51512072&amp;newsitemid=20170220005035&amp;lan=en-US&amp;anchor=Foundation+for+the+National+Institutes+of+Health%C2%A0&amp;index=4&amp;md5=ede3d2725647ee1b6a9e801729fa24fb" rel="nofollow" rel="nofollow">Foundation 
 for the National Institutes of Health </a>(FNIH), will create an 
 electronic platform to validate key PROs, allowing investigators to 
 assess the symptoms of ABSSSI, CABP and HABP at various time points over 
 the course of the infection and measure the effects of antibacterial 
 drugs. The PROs will be implemented on CRF Health's TrialMax® eCOA 
 platform, allowing patients to use the application on a handheld device 
 during the course of the trials. These PROs will continue to be 
 validated and developed in accordance with the FDA guidance for PRO 
 measures used to support labeling claims and will follow the Drug 
 Development Tool (DDT) Qualification Program.
 
 
 The collaboration brings together scientists from ICON, FNIH, the FDA, 
 the <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niaid.nih.gov%2F&amp;esheet=51512072&amp;newsitemid=20170220005035&amp;lan=en-US&amp;anchor=National+Institute+of+Allergy+and+Infectious+Diseases&amp;index=5&amp;md5=7c357fbd2cc4f2ff984590bb8dee7419" rel="nofollow" rel="nofollow">National 
 Institute of Allergy and Infectious Diseases</a>, the <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.idsociety.org%2FIndex.aspx&amp;esheet=51512072&amp;newsitemid=20170220005035&amp;lan=en-US&amp;anchor=Infectious+Diseases+Society+of+America&amp;index=6&amp;md5=2882a9e966291c17b7078f93226b5165" rel="nofollow" rel="nofollow">Infectious 
 Diseases Society of America</a>, pharmaceutical and biotechnology 
 companies and the academic research community, to develop new approaches 
 for evaluating the efficacy of antibiotics in future clinical trials of 
 therapies for ABSSSI, CABP and HABP.
 
 
 "This project builds on our previous work with the FDA and FNIH to 
 develop a new PRO measure for HABP trials and we're proud to continue 
 our support in this area of great unmet need," commented Ramita 
 Tandon, Executive Vice President, ICON Commercialisation &amp; Outcomes. "Bacterial 
 infections are becoming harder to treat as drug-resistant strains emerge 
 at an increasing rate. ICON's COA group has extensive experience in all 
 areas of outcomes research to validate these important endpoints for 
 antibacterial trials, speeding up the drug development process and 
 delivering effective antibacterial medicines to patients."
 
 
 About ICON plc
 
 
 ICON plc is a global provider of drug development solutions and <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.iconplc.com%2Fservices&amp;esheet=51512072&amp;newsitemid=20170220005035&amp;lan=en-US&amp;anchor=services&amp;index=7&amp;md5=fd3a38063cf454ae78530234cbf0f5ec" rel="nofollow" rel="nofollow">services</a> 
 to the pharmaceutical, biotechnology and medical device industries. The 
 company specialises in the strategic development, management and 
 analysis of programs that support clinical development - from compound 
 selection to Phase I-IV clinical studies. With headquarters in Dublin, 
 Ireland, ICON currently, operates from 87 locations in 38 countries and 
 has approximately 12,500 employees. Further information is available at <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.iconplc.com&amp;esheet=51512072&amp;newsitemid=20170220005035&amp;lan=en-US&amp;anchor=www.iconplc.com&amp;index=8&amp;md5=f24f799b585711e719be014b37ddcc6d" rel="nofollow" rel="nofollow">www.iconplc.com</a>.
 
 
 About the FNIH
 
 
 The Foundation for the National Institutes of Health creates and manages 
 alliances with public and private institutions in support of the mission 
 of the NIH, the world's premier medical research agency. The Foundation, 
 also known as the FNIH, works with its partners to accelerate key issues 
 of scientific study and strategies against diseases and health concerns 
 in the United States and across the globe. The FNIH organizes and 
 administers research projects; supports education and training of new 
 researchers; organizes educational events and symposia; and administers 
 a series of funds supporting a wide range of health issues. Established 
 by Congress in 1996, the FNIH is a not-for-profit 501(c)(3) charitable 
 organization. Further information is available at <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fnih.org&amp;esheet=51512072&amp;newsitemid=20170220005035&amp;lan=en-US&amp;anchor=www.fnih.org&amp;index=9&amp;md5=28d890ac5da06cf870225992ce4de41d" rel="nofollow" rel="nofollow">www.fnih.org</a>
 
 
 About the Biomarkers Consortium
 
 
 The Biomarkers Consortium is a public-private biomedical research 
 partnership managed by the Foundation for the National Institutes of 
 Health (FNIH) that endeavors to develop, validate, and/or qualify 
 biological markers (biomarkers) to speed the development of medicines 
 and therapies for detection, prevention, diagnosis and treatment of 
 disease and improve patient care.
 
 
 Further information is available at <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.biomarkersconsortium.org&amp;esheet=51512072&amp;newsitemid=20170220005035&amp;lan=en-US&amp;anchor=www.biomarkersconsortium.org&amp;index=10&amp;md5=184c7d59791f7f807aa98c8e3722c26f" rel="nofollow" rel="nofollow">www.biomarkersconsortium.org</a>
 
 
 About CRF Health
 
 
 CRF Health is the leading provider of patient-centered eSource 
 technology and service solutions for the life sciences industry. With 
 experience in more than 800 trials, over 100 languages and across 74 
 countries, CRF Health's TrialMax® platform consistently demonstrates the 
 industry's highest data accuracy, patient and site compliance, and 
 patient retention.
 
 
 CRF Health's eSource solutions improve trial engagement by fitting into 
 the lives of patients and seamlessly integrating into sites to maximize 
 protocol compliance. The integrated TrialMax® platform includes eCOA 
 solutions for collecting PROs (Patient Reported Outcomes), ObsROs 
 (Observer Reported Outcomes), ClinROs (Clinician or Rater Reported 
 Outcomes), and PerfOs (Performance Outcomes), and features 
 TrialConsent™, an electronic solution for collecting informed consent in 
 clinical trials. More information is at <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.crfhealth.com%2F&amp;esheet=51512072&amp;newsitemid=20170220005035&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.crfhealth.com%2F&amp;index=11&amp;md5=6b3baea22f603d1fdfe68db1cec0e6c8" rel="nofollow" rel="nofollow">http://www.crfhealth.com/</a>
 
 
 This press release contains forward-looking statements. These 
 statements are based on management&#39;s current expectations and 
 information currently available, including current economic and industry 
 conditions. These statements are not guarantees of future performance or 
 actual results, and actual results, developments and business decisions 
 may differ from those stated in this press release. The forward-looking 
 statements are subject to future events, risks, uncertainties and other 
 factors that could cause actual results to differ materially from those 
 projected in the statements, including, but not limited to, the ability 
 to enter into new contracts, maintain client relationships, manage the 
 opening of new offices and offering of new services, the integration of 
 new business mergers and acquisitions, as well as economic and global 
 market conditions and other risks and uncertainties detailed from time 
 to time in SEC reports filed by ICON, all of which are difficult to 
 predict and some of which are beyond our control. For these reasons, you 
 should not place undue reliance on these forward-looking statements when 
 making investment decisions. The word &#34;expected&#34; and variations of such 
 words and similar expressions are intended to identify forward-looking 
 statements. Forward-looking statements are only as of the date they are 
 made and we do not undertake any obligation to update publicly any 
 forward-looking statement, either as a result of new information, future 
 events or otherwise. More information about the risks and uncertainties 
 relating to these forward-looking statements may be found in SEC reports 
 filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are 
 available on the SEC&#39;s website at <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Furldefense.proofpoint.com%2Fv1%2Furl%3Fu%3Dhttp%3A%2F%2Fwww.sec.gov.%26k%3DO82v1QPk8v0F4rUQzzlDIA%253D%253D%250A%26r%3Dtx5RTZGGN%252Bj%252FP1Q1hxZ8WtJFA7oGnvclXKE9%252F3CJssI%253D%250A%26m%3DC%252BDFebmEXvEee67y1S96%252FVAdeXlCrzUKXWTrX8fNWXU%253D%250A%26s%3D520f928f8f4ef39f62d95156e0b70115302f2d248aca553a7b006d40b3842344&amp;esheet=51512072&amp;newsitemid=20170220005035&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.sec.gov.&amp;index=12&amp;md5=8a8362d39fefc0d52c5be842952cc3c8" rel="nofollow" rel="nofollow">http://www.sec.gov.</a>
 
 
 ICON/ICLR-G
 
 <img xmlns="http://www.w3.org/1999/xhtml" alt="" src="http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20170220005035r1&amp;sid=benz2&amp;distro=nx&amp;lang=en"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.businesswire.com/news/home/20170220005035/en/" rel="nofollow" rel="nofollow">http://www.businesswire.com/news/home/20170220005035/en/</a></body></html>

Press Releases

ICON Selected by the FDA to Validate Patient-Reported Outcome Endpoints for Antibacterial Drug Trials - Icon (NASDAQ:ICLR)

Icon

ICLR

ICON Selected by the FDA to Validate Patient-Reported Outcome Endpoints for Antibacterial Drug Trials


Inaugural Video Spotlights Company&#39;s Eco Vision and Commitment to Wood as the Future of Sustainable Construction


T2EARTH, an eco-friendly, USA based, building materials and wood science technology company, is

T2EARTH Launches Official YouTube Channel – T2EARTH Talks


In 1970, the inaugural Earth Day marked a pivotal moment in history, galvanized by the collective efforts of over 20 million passionate individuals. Spearheaded by Senator Gaylord Nelson, this landmark event resonated

T2EARTH Celebrates Earth Day by Leading the Wood Products Industry towards a Sustainable Built Environment


**For High-Res Images from the Grand Opening, click here**
**For Wolf by Vanderpump Images, click here**


Last night, television star and restaurateur Lisa Vanderpump hosted a

Television Star and Restaurateur Lisa Vanderpump Hosts Grand Opening of Wolf by Vanderpump at Harveys Lake Tahoe

KVUE


Dean Omar Branham Shirley represents family of deceased woman


A jury in the Circuit Court of Cook County in Chicago found Johnson &amp; Johnson (NYSE:JNJ) and two subsidiaries liable in the asbestos-related death of a

Illinois Jury Awards $45 Million in Mesothelioma Case Against Johnson &amp; Johnson, Kenvue, Inc.

ALMTF

TSX:AII


Almonty Industries Inc. (&#34;Almonty&#34; or the &#34;Company&#34;) (TSX:AII, OTCQX:ALMTF) is pleased to announce that, further to its news release dated March 22, 2024, it has closed three tranches of its non-brokered private

Almonty Closes Additional Tranches of Private Placement


Sandata stands in support of all homecare providers in New York and opposes state legislation that negatively impacts CDPAP.


Sandata, a leading provider of Agency Management, Electronic Visit Verification (EVV) and